MyJournals Home  

RSS FeedsIpilimumab-Induced Enterocolitis: A Systematic Review and Meta-Analysis (Drug Safety)


4 august 2020 08:21:27

Ipilimumab-Induced Enterocolitis: A Systematic Review and Meta-Analysis (Drug Safety)

Abstract Introduction Checkpoint inhibitor drugs including ipilimumab have been reported to induce intestinal injury. Objective We aimed to evaluate the risk of chronic (> 6 weeks) enterocolitis following ipilimumab administration, and the likelihood that an enteritis vs colitis or enterocolitis is seen. Patients and Methods We searched MEDLINE, EMBASE, CENTRAL, the World Health Organization International Clinical Trials Registry, and conference proceedings. We included: (1) randomized controlled trials comparing ipilimumab administration with placebo/standard care/other active chemotherapy regimens and (2) prospective observational studies. Separate meta-analyses were performed for randomized controlled trials and observational studies. Results Of 4760 records, we included ten unique randomized controlled trials (n = 5814 subjects) and 34 unique prospective observational studies (n = 3699 subjects). In randomized controlled trials, the pooled relative risk of ≥ grade 3 enterocolitis or ≥ grade 3 diarrhea associated with ipilimumab was 13.31 (95% confidence interval 6.01–29.48, I2 = 0%, ten trials) and 6.72 (95% confidence interval 3.30–13.65, I2 = 63%, ten trials), respectively. In observational studies, the 3-monthly risk of developing grade 3 or higher enteritis, colitis, or enterocolitis was 4% (95% confidence interval 3–7, I2 = 77.40%, 25 studies). Randomized controlled trials and observational studies did not distinguish between acute and chronic enterocolitis. Of the included observational studies, the pooled risk of incurring small bowel involvement associated with ipilimumab was 1% (95% CI 0–4, I2 = 0%, four studies) per every 3-month time period. Conclusions Insufficient data exist to quantify or distinguish the risk of acute vs chronic enterocolitis following ipilmumab use. Because of the serious impact of chronic enterocolitis on quality of life and further cancer treatment, future trials evaluating the safety of immunotherapy should report gastrointestinal events in greater detail.

82 viewsCategory: Pharmacology
[ASAP] Poly(caprolactone)-Based Coatings on 3D-Printed Biodegradable Implants: A Novel Strategy to Prolong Delivery of Hydrophilic Drugs (Molecular Pharmaceutics)
[ASAP] Delivery of Platinum(IV) Prodrugs via Bi2Te3 Nanoparticles for Photothermal–Chemotherapy and Photothermal/Photoacoustic Imaging (Molecular Pharmaceutics)
blog comments powered by Disqus
The latest issues of all your favorite science journals on one page


Register | Retrieve



Copyright © 2008 - 2020 Indigonet Services B.V.. Contact: Tim Hulsen. Read here our privacy notice.
Other websites of Indigonet Services B.V.: Nieuws Vacatures News Tweets Nachrichten